DLBS1033 as Adjunctive Therapy for Patients With Diabetic Neuropathy

Inclusion Criteria: * Patients diagnosed with diabetic neuropathy based on symptoms and clinical signs of peripheral neuropathy and a Toronto Clinical Neuropathy Score (TCNS) of 6 or higher, representing mild to severe neuropathy. * Age 18 years or older. * Willing to participate in the study and sign the informed consent form. * Able to complete the study procedures and complete the Short Form-36 quality of life questionnaire independently or with assistance from the investigator if needed. Exclusion Criteria: * Participants with other conditions that may cause non-diabetic peripheral neuropathy, including history of chemotherapy, use of anti-tuberculosis drugs such as isoniazid, heavy alcohol consumption, chronic kidney disease, liver cirrhosis, vitamin B12 deficiency, hypothyroidism, HIV/AIDS, hereditary neuropathy, or neuromuscular disease affecting the peripheral nerves. * Participants with acute infection or active inflammatory conditions that may affect interleukin-8 and Galectin-3 levels at the time of sample collection before or after intervention, such as acute infection with fever, infection with systemic manifestations, active malignancy, or active inflammatory autoimmune disease. * Allergy or history of hypersensitivity to the active ingredient of DLBS1033. * Currently receiving another experimental therapy or participating in another clinical study. * Pregnant or breastfeeding women.